{"id":"d377","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Limited publicly available information exists regarding the specific mechanism of action for D377. As a phase 3 candidate from Chong Kun Dang Pharmaceutical, it has progressed through early clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.","oneSentence":"D377 is an investigational therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:22.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05657574","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-11-24","conditions":"Primary Hypercholesterolemia","enrollment":228}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D377","genericName":"D377","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}